Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may untangle vanishing twin puzzle to screen the survivor

NCT ID NCT05004337

Diagnosis Sponsor: Natera, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 17, 2026 · Last updated Aug 18, 2026 · Updated 1 time

Summary

This study is testing whether a blood test can tell apart the DNA from a vanishing twin and the living twin in pregnancies where one twin stops developing. The goal is to improve non-invasive prenatal screening for chromosome conditions like trisomy 21, 18, and 13 in the surviving twin. Researchers will collect blood samples from women with dizygotic twin pregnancies and use genetic analysis to develop a new algorithm that can measure each twin's DNA separately. If it works, this could lead to more accurate prenatal screening for these pregnancies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
SNP-based non-invasive prenatal testing (NIPT) using a blood sample
What this could lead to
If successful, this could improve prenatal screening for women with vanishing twin pregnancies, giving clearer information about the health of the surviving twin.
What could go wrong
The study is small and early, and the algorithm may not be accurate enough for all cases. There is also a risk of false results, which could cause unnecessary worry.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

136 people

The number who actually took part.

Started

Jul 2021

Finished

Nov 2023

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Pregnant women carrying a vanishing twin pregnancy

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women with either ultrasound-documented dizygotic (DZ) twin pregnancy or those whose Panorama Test™ results suggest increased risk for vanishing twin Exclusion Criteria: * Monozygotic twin pregnancy * Non twin pregnancy * Maternal history of bone marrow or organ transplantation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Trisomy 13 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Down syndrome trisomy 13 Trisomy 13 Syndrome trisomy 18 Trisomy 18 Syndrome trisomy 21

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Trisomy 13 Trisomy 18 Trisomy 21 Vanishing twin

Contacts and locations

Locations

  • Beaumont

    Royal Oak, Michigan, 48073, United States

  • Cedar Health Research

    Irving, Texas, 75039, United States

  • Center for Fetal Medicine & Women's Ultrasound

    Los Angeles, California, 90048, United States

  • Christiana Care

    Newark, Delaware, 19718, United States

  • Columbia University

    New York, New York, 10032, United States

  • Emerald Coast ObGyn

    Panama City, Florida, 32405, United States

  • Hackensack

    Neptune City, New Jersey, 07753, United States

  • Icahn School of Medicine at Mount Sinai Hospital

    New York, New York, 10029, United States

  • Lehigh Valley Health Network

    Allentown, Pennsylvania, 18103, United States

  • Mayo Clinic

    Rochester, Minnesota, 55905, United States

  • Montefiore Medical Center

    The Bronx, New York, 10461, United States

  • NYU Langone

    New York, New York, 10022, United States

  • NYU Long Island

    Mineola, New York, 11501, United States

  • St. Peter's University Hospital

    New Brunswick, New Jersey, 08901, United States

  • Stanford

    Palo Alto, California, 94304, United States

  • University of Colorado

    Aurora, Colorado, 80045, United States

  • University of Kansas

    Kansas City, Kansas, 66160, United States

  • University of Michigan

    Ann Arbor, Michigan, 48109, United States

  • University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

  • Weill Cornell Medicine

    New York, New York, 10065, United States

  • Yale

    New Haven, Connecticut, 06511, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.